EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 475 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Cancer in My Community: How People With Cancer Access Care in... August 12, 2021 Boy Asks Mom Fighting Cancer To Take Off Her Turban So... May 4, 2020 Cauliflower Rice August 28, 2020 Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced... July 21, 2021 Load more HOT NEWS UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel pCR Associated with Improved Survival Outcomes in Patients with Soft Tissue...
